Background and objectives: The value of a complete remission in severe lupus nephritis is well known but little is known about the impact of a partial remission in this patient population. The purpose of this study was to evaluate the long-term prognosis of achieving a complete or partial remission in a well-defined group of patients with severe lupus nephritis.
I
n severe lupus nephritis, a significant correlation between response to aggressive immunosuppressive treatment as measured by a reduction or remission in proteinuria and outcomes has been demonstrated (1-6). As a result, the use of remission as a short-term outcome has been suggested as a valid measure when designing future studies given the ability to predict long-term outcomes that generally are used, such as ESRD, doubling of serum creatinine, and death (1) . The majority of studies that assessed response to treatment in patients with severe lupus nephritis focused on outcomes based on attaining a complete remission (CR) (2,6 -9) . Although the definition of a CR can vary considerably from study to study (1), we previously showed that when strictly defining a CR as a normalization in proteinuria and serum creatinine, patients who attained a CR with aggressive immunosuppressive treatment had significantly better patient and renal survivals than nonresponders (6) . Little is known, however, of the outcomes in patients who have severe lupus nephritis and are unable to attain a normalization of renal parameters but have a partial response to therapy with a reduction in proteinuria and stabilization in renal function. In other forms of glomerular disease, attaining a "partial remission" (PR) has resulted in significant improvement in renal outcomes (10, 11) . Whether a similar experience can be observed in patients with severe lupus nephritis is unknown. The purpose of this study was to evaluate the long-term prognosis of achieving a PR in a well-defined group of patients with severe lupus nephritis.
CONCISE METHODS

Patients
The 86 adult patients who participated in the prospective, controlled trial of plasmapheresis in severe lupus nephritis that was conducted from April 1981 to December 1988 compose the study group (12) . Because there were no significant differences between the two treatment groups during the therapeutic trial, the patient data were pooled for this study (12) . During the course of the study, 37 (43%) patients entered a CR, 21 (24%) entered a PR, and 28 (33%) were nonresponsive to therapy.
The entry criteria, therapeutic and medical management protocols, and results of the initial study have been previously described (12, 13) . In brief, patients were eligible when they were Ն16 yr of age, had systemic lupus erythematosus as defined by the American Rheumatism Association (14) , and had biopsy-proven severe lupus nephritis. Patients with a serum creatinine Ͼ6 mg/dl, previous plasmapheresis, or pregnancy were excluded from the study.
Entry criteria (12) Because we previously showed that the prognosis of these lesions is defined by the distribution of their proliferative component (segmental versus global inflammation), we grouped them accordingly into category III Ն50% (44 patients) and category IV (41 patients) (20) . These histologic classes are similar to class IV-S (segmental) Ϯ V and IV-G (global) Ϯ V in the classification proposed by the International Society of Nephrology and Renal Pathology Society (ISN/RPS) (21, 22) , but there are important differences. In the classification used by the Lupus Nephritis Collaborative Study Group (15) (16) (17) , a segmental lesion (class III Ն50%) can involve anywhere from 50% of glomeruli to all of the glomeruli in the biopsy, and there was no upper limit to the extent of involvement within each glomerulus. In contrast, the ISN/RPS classification relegates biopsies with segmental lesions that involve Ͼ50% of the glomerular tuft to class IV-G. As a result, inclusion of very widely distributed segmental lesions to ISN/RPS class IV-G could easily conceal differences in outcomes between patients with class IV-S and IV-G. Because this article addresses critical differences in outcomes in segmental and diffuse glomerular lesions on the basis of remission status, we continue to use the original classification.
Clinical, biochemical, and serologic information was obtained on patients at baseline and at specified follow-up times during the initial study. The study was terminated in March 1986, but patients were formally followed through December 1988 (12) . Clinical follow-up has now been extended to June 1998. Information on current clinical status of the patients with respect to death, ESRD, and biochemical results for serum creatinine and urine protein were recorded.
Laboratory Analysis
Baseline serum creatinine, C3 and C4 complement components, antidouble-stranded DNA antibodies (anti-dsDNA), C1q binding activity, and cryoglobulin concentrations were determined in a central laboratory as described previously (23) . Serum creatinine was measured by a Creatinine Analyzer II (Beckman Instruments, Fullerton, CA) with the use of a modified alkaline picrate method. Serum C3 and C4 were measured by radial immunodiffusion (Calbiochem-Behring, La Jolla, CA), and anti-dsDNA was measured by RIA (Amersham, Arlington Heights, IL). Antibodies to Ro, La, nRNP, and Sm were determined by Dr. Morris Reichlin, MD (Oklahoma City, OK) using an ELISA with affinity-purified antibodies as described previously (24, 25) .
Treatment Protocol
The details of the treatment protocols for this study have been published previously (12,13). All patients initially received 60 mg/d prednisone orally and 2 mg/kg per d cyclophosphamide orally. Forty patients were randomly assigned to receive standard therapy plus plasmapheresis three times weekly for 4 wk in addition to this treatment. After the initial 4 wk of treatment, patients who improved clinically received cyclophosphamide at 1 mg/kg per d for an additional month, after which it was discontinued. The dosage of prednisone was gradually tapered over a 22-wk period to 20 mg on alternate days. Patients whose renal symptoms had worsened at 4 wk were continued on the initial high-dosage prednisone and cyclophosphamide for an additional 4 wk, and patients in the plasmapheresis arm of the study also received an additional 12 treatments. Thereafter, renal and extrarenal flares were treated on the basis of other standardized protocols of intensive drug therapy as described previously (13) .
Outcome Variables
The following outcomes were evaluated from the time of entry into the study: (1) Time to CR (serum creatinine of Յ1.4 mg/dl and proteinuria of Յ0.33 g/d within 5 yr of entering the study); (2) time to PR (a Յ25% increase in baseline creatinine and Ն50% reduction in baseline proteinuria to Յ1.5 g/d [but Ͼ0.33 g/d] within 5 yr of entering the study); (3) time to ESRD (defined by a serum creatinine of Ն6 mg/dl or the initiation of renal replacement therapy); and (4) time to death. Lupus renal flares were defined as moderate (a sudden increase in serum creatinine of Ͼ0.3 mg/dl or an increase in proteinuria of Ͼ1.0 g/d) or severe (a sudden increase in serum creatinine of Ͼ1 mg/dl [12, 13] (26) . Results are reported as mean Ϯ SD, and P Ͻ 0.05 was considered significant.
Results
Baseline Clinical and Serologic Characteristics
During the course of the study, 37 (43%) patients entered a CR, 21 (24%) entered a (PR), and 28 (33%) had no remission (NR).
The baseline clinical and serologic characteristics on the basis of remission status are shown in Table 1 . There were no significant differences in age, gender, black race, BP, level of proteinuria, or treatment among the groups at baseline; however, the serum creatinine at baseline was significantly different among the groups. The serum creatinine was highest in patients with NR compared with patients who went on to attain a CR or PR, and the serum creatinine was significantly lower in patients with CR compared with both patients with a PR and NR. There were no significant differences in serologic parameters among the groups at baseline (Table 2) .
Histologic Features
The histologic features at biopsy are shown in Table 3 . Whereas the proportion of patients with WHO III Ն50% and WHO IV lesions were not significantly different among the three groups, patients with CR were more likely to have category IV lesions than patients with PR or NR, and patients with NR were more likely to have WHO III Ն50% lesions compared with CR and PR patients. On the basis of WHO classification (IV versus III Ն50%), a CR was observed in 56 versus 32% of patients, a PR was observed in 20 versus 27% of patients, and there was no response in 24 versus 41% of patients (P ϭ 0.07 overall). There were no differences in the activity index or the proportion of patients with an activity index Ն12 among the groups; however, the chronicity index and the proportion of patients with a chronicity index Ն4 was significantly lower in patients who achieved CR compared with both patients who attained a PR or NR.
Follow-up
Patients with CR or PR had significantly longer lengths of follow-up compared with patients with NR ( Table 4 ). The time to achieve a CR was more than twice that compared with patients who achieved a PR (Table 4 , Figure 1 ). The proportion of patients who had renal flares was significantly less in patients with a CR compared with patients with a PR. At last follow-up, patients who entered a CR had a significantly greater proportion with stable renal function and significantly lower proportion who had progressed to ESRD or had a renal death (progressed to ESRD and then died) than both patients with PR or NR. In addition, more than twice as many patients with PR had stable renal function (29 versus 11%; P ϭ 0.14) and half as many deaths (renal death ϩ nonrenal death; 28 versus 54%, P ϭ 0.14) compared with patients with NR, but this was not statistically different.
Survival Outcomes
The renal survival (Figure 2 ) was significantly greater for patients wit CR and PR (median 100.9 mo) compared with pa- tients with NR (median 17.8 mo; P Ͻ 0.0001 and P ϭ 0.003, respectively). Renal survival for patients with CR was also significantly better than for patients with PR (P Ͻ 0.0001). The renal survival at 10 yr was 94% for CR, 45% for PR, and 19% for NR. Patient survival (Figure 3 ) was also greatest for patients who achieved CR and PR compared with NR (median 115 mo; P Ͻ 0.0001 and P ϭ 0.03, respectively). Patient survival for patients with CR was also significantly better than for patients with PR (P ϭ 0.01). The patient survival at 10 yr was 95% for CR, 76% for PR, and 41% for NR. Finally, patient survival without ESRD (Figure 4 ) was also significantly better for patients with CR and PR (median 99.9 mo) compared with NR (median 8.2 mo; P Ͻ 0.0001 and P ϭ 0.0005, respectively). Patient survival without ESRD for patients with CR was significantly better than for patients with PR (P Ͻ 0.0001). The patient survival without ESRD at 10 yr was 92% for CR, 43% for PR, and 13% for NR. In addition, the patient survival without ESRD was similar overall for patients who initially were treated with plasmapheresis compared with those who were treated with standard therapy (median 132 versus 133 mo; P ϭ 0.83).
Discussion
We previously demonstrated that patients who had severe lupus nephritis and entered a CR, defined by normalization in renal function and proteinuria, with aggressive immunosuppressive therapy have an excellent patient and renal survival compared with patients with NR (6) . In this study, we found that even patients with a PR, achieving a halving of proteinuria and have proteinuria Յ1.5 g/d and Յ25% increase in serum creatinine, also had significantly better outcomes than patients who did not attain a remission but not as good as in patients with CR. Patients who attained a CR had a lower serum creatinine at baseline compared with patients with a PR or no remission. In addition, patients with a CR had less advanced renal disease as demonstrated by a lower chronicity index. Otherwise, there were no differences in baseline clinical, serologic, or histologic features between patients who attained a CR or PR or NR. The goal of therapy in patients with proliferative lupus nephritis is the attainment of a response or remission in proteinuria given the excellent prognosis. Houssiau et al. (4) showed that the positive predictive value for a good long-term renal outcome is 90% in patient who have a reduction in proteinuria of 50 to 75% by 6 mo and 87% for patients with proteinuria Ͻ1 g/d. As we and others have shown, in patients who normalize their renal function (a CR), the renal survival at 10 yr is excellent (Ͼ90%) compared with 30 to 50% for patients with NR (2,6). CR rates vary considerable among studies of patients with proliferative or severe lupus nephritis, ranging from 10 to 85%. This variability most likely results from differences in definitions, therapeutic protocols, and patient mix. The goal of this study was to assess the impact of a remission (CR or PR) and not to determine the optimal therapeutic protocol. There is no agreed-on criteria to define response or remission in lupus nephritis. The definitions for remission, often referred to as complete, range from those that require a reduction in proteinuria to essentially normal levels Ͻ0.3 to 0.5 g/d (6, 8, (27) (28) (29) (30) to those that require improvement to Յ1.0 g/d (9,31) and those that require only a Ն30% reduction in proteinuria to Ͻ3 g/d (32) . In addition, renal function as measured by serum creatinine level must be normal in some studies (6, 27) , whereas in others, it must be "stable" (i.e., Ͻ30% rise in serum creatinine) or "improved" (9, 28) or there must be a lack of doubling serum creatinine (31) . In our study, we chose to apply the term CR to patients who achieved a normalization in renal function and proteinuria because the outcome for these patients is significantly improved over that for patients with NR.
Few studies in severe lupus nephritis have assessed for the attainment of a PR. When evaluated, the attainment of a PR ranges from 10 to 50%, and, in this case, the definitions applied are even more variable (8, 9, 33, 34) . Some studies merely required proteinuria to be "fixed" or "improved" (9) , whereas others required a 50% reduction in proteinuria (35) , a 50% reduction in proteinuria to a level of proteinuria of 1 to Ͻ3 g/d (34, 36) , a 50% reduction in proteinuria to a level of 0.3 to Ͻ3 g/d (8, 33, 37) , or a reduction in proteinuria to Յ1 g/d (29) . Renal function requirements, although not always specified, include remaining stable or improved, Ն50% improvement from baseline, or lack of worsening from baseline of Յ25 to 50%. Unfortunately, none of these studies assessed the impact of attaining a PR.
Using a definition of PR that requires a 50% reduction in proteinuria to Յ1.5 g/d and stable renal function, we found that 24% of our patients with severe lupus nephritis attained this level of response. Furthermore, we found that their outcomes were significantly better than those of patients who did not achieve these goals. These observations are consistent with the findings of Cortes-Hernandez et al. (5) , who found that patients who had diffuse proliferative lupus nephritis and attained proteinuria of Ͻ2 g/d had a renal survival at 8 yr of 100% compared with 40% for those with proteinuria Ͼ2 g/d. Thus, attainment of a PR to the level of function as defined in this study has clinical benefit.
The time to attaining a CR is significantly longer than that required to attain a PR, and this is expected given the more strict criteria for a CR. The average time to a CR in our study was 16 mo with a median time of 10.5 mo compared with a median of 5.8 mo for a PR. The timing for a CR is consistent with that observed by Chan et al. (8) , whose patients entered a CR by 15 mo on average, and by Ioannidis et al. (32) , who reported a median time to remission of 10 mo. On the basis of these observations, it is understandable why studies with only 6 mo of follow-up, such as that by Ginzler et al. (35) , reported a low CR rate and relatively high PR rate.
A number of features at baseline have been found to be predictive of a CR and these include race, level of serum, level of proteinuria, and chronicity index (6, 7, 34) . In this study, we continued to find that patients who entered a CR had less advanced renal disease compared with patients with a PR or no remission; however, we were unable to find any features that could predict which patients would enter a PR because there were no significant differences at baseline between patients who attained a PR and NR. Ioannidis et al. (32) found that one of the most significant predictors of a failure to attain a remission is the delay in the time from diagnosis of nephritis to the initiation of therapy. A delay in treatment of Ͼ3 mo resulted in a 42% reduction in likelihood of attaining a remission in proteinuria (defined by a Ն30% reduction in proteinuria to Ͻ3 g/d). These observations emphasize the importance of early diagnosis and treatment.
Although the favorable impact of a CR has been shown in a number of studies, no study before ours independently assessed the impact of a PR in severe lupus nephritis. The value of a PR in our study is consistent with that in other forms of glomerular disease, in which renal survival in patients with a PR is intermediate being less than that for patients who entered a CR but significantly better than that for patients with NR (10, 11) . The importance of maintaining a remission has been emphasized in patients with lupus nephritis because patients with renal flares are six times as likely to progress to ESRD as those without a flare (27) . Although we found that the proportion of patients with moderate to severe renal flares was higher in patients with PR compared with patients with a CR, the outcomes were still significantly better than for patients who never entered a remission. Nonetheless, the increase in flares in patients with a PR and the poorer outcomes compared with patients with CR underscores the recent warning that PR should not be an end point that results in discontinuation of treatment (38) . Rather, patients with PR, possibly even more than patients with CR, will require ongoing maintenance therapy to minimize flares and reduce the potential for progressive renal disease.
Conclusions
On the basis of our therapeutic approach and definitions for remission, we found that even a PR in patients with severe lupus nephritis led to significant improvement in outcomes compared with patients who achieved NR. Despite this, the goal of therapy in severe lupus nephritis remains the attainment of a CR as defined by normalization of proteinuria and renal function because the outcomes for these patients remain far superior compared with those for patients with a PR. The finding that patients with CR have less advanced renal disease than patients with PR or NR stresses the importance of early detection and aggressive treatment of severe lupus nephritis.
